Document Detail

Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.
MedLine Citation:
PMID:  7671238     Owner:  NLM     Status:  MEDLINE    
Thioredoxin, a cellular thiol, functions as a self-defense mechanism in response to environmental stimuli, including oxidative stress. We first determined cellular levels of thioredoxin in several human bladder and prostatic cancer cell lines resistant to cis-diamminedichloroplatinum(II) (cisplatin). All cisplatin-resistant cell lines had much higher levels of thioredoxin than those in their drug-sensitive parental counterpart. We then, by introducing thioredoxin antisense expression plasmids into human bladder cancer T24 cells, established two bladder cancer cell lines that had decreased levels of thioredoxin. These thioredoxin antisense transfectants showed increased sensitivity to cisplatin and also to other superoxide-generating agents, i.e., doxorubicin, mitomycin C, etoposide, and hydrogen peroxide, as well as to UV irradiation, but not to the tubulin-targeting agents, vincristine, and colchicine. Cellular levels of thioredoxin thus appear to limit sensitivity to various superoxide-generating anticancer drugs in cancer cells.
A Yokomizo; M Ono; H Nanri; Y Makino; T Ohga; M Wada; T Okamoto; J Yodoi; M Kuwano; K Kohno
Related Documents :
17727798 - Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating d...
21622238 - Microglia-friend or foe.
20824508 - Assessing p-glycoprotein (pgp) activity in vivo utilizing (68)ga-schiff base complexes.
10811448 - Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cell...
8126058 - Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellul...
23522958 - Mouse models for studying angiogenesis and lymphangiogenesis in cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer research     Volume:  55     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1995-10-19     Completed Date:  1995-10-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4293-6     Citation Subset:  IM    
Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Cisplatin / pharmacology*
DNA / metabolism
Dose-Response Relationship, Drug
Doxorubicin / pharmacology*
Drug Resistance
Etoposide / pharmacology*
Mitomycin / pharmacology*
Thioredoxins / metabolism*
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 50-07-7/Mitomycin; 52500-60-4/Thioredoxins; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Next Document:  Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.